Author/Authors :
Paul Beswick، نويسنده , , Sharon Bingham، نويسنده , , Chas Bountra، نويسنده , , Terry Brown، نويسنده , , Kerry Browning، نويسنده , , Ian Campbell، نويسنده , , Iain Chessell، نويسنده , , Nick Clayton، نويسنده , , Sue Collins، نويسنده , , John Corfield، نويسنده , , Stephen Guntrip، نويسنده , , Claudine Haslam، نويسنده , , Paul Lambeth، نويسنده , , Fiona Lucas، نويسنده , , Neil Mathews، نويسنده , , Graham Murkit، نويسنده , , Alan Naylor، نويسنده , , Neil Pegg، نويسنده , , Elizabeth Pickup، نويسنده , , Hazel Player، نويسنده , , et al.، نويسنده ,
Abstract :
GW406381 (8), currently undergoing clinical evaluation for the treatment of inflammatory pain is a member of a novel series of 2,3-diaryl-pyrazolo[1,5-b]pyridazine based cyclooxygenase-2 (COX-2) inhibitors, which have been shown to be highly potent and selective. Several examples of the series, in addition to possessing favourable pharmacokinetic profiles and analgesic activity in vivo, have also demonstrated relatively high brain penetration in the rat compared with the clinically available compounds, which may ultimately prove beneficial in the treatment of pain.
